Publication: Engineered human monoclonal scfv to receptor binding domain of ebolavirus
Issued Date
2021-05-01
Resource Type
ISSN
2076393X
Other identifier(s)
2-s2.0-85106193619
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccines. Vol.9, No.5 (2021)
Suggested Citation
Jaslan Densumite, Siratcha Phanthong, Watee Seesuay, Nitat Sookrung, Urai Chaisri, Wanpen Chaicumpa Engineered human monoclonal scfv to receptor binding domain of ebolavirus. Vaccines. Vol.9, No.5 (2021). doi:10.3390/vaccines9050457 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/77292
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Engineered human monoclonal scfv to receptor binding domain of ebolavirus
Other Contributor(s)
Abstract
(1) Background: Ebolavirus (EBOV) poses as a significant threat for human health by frequently causing epidemics of the highly contagious Ebola virus disease (EVD). EBOV glycoprotein (GP), as a sole surface glycoprotein, needs to be cleaved in endosomes to fully expose a receptor-binding domain (RBD) containing a receptor-binding site (RBS) for receptor binding and genome entry into cytoplasm for replication. RBDs are highly conserved among EBOV species, so they are an attractive target for broadly effective anti-EBOV drug development. (2) Methods: Phage display technology was used as a tool to isolate human single-chain antibodies (HuscFv) that bind to recombinant RBDs from a human scFv (HuscFv) phage display library. The RBD-bound HuscFvs were fused with cell-penetrating peptide (CPP), and cell-penetrating antibodies (transbodies) were made, produced from the phage-infected E. coli clones and characterized. (3) Results: Among the HuscFvs obtained from phage-infected E. coli clones, HuscFvs of three clones, HuscFv4, HuscFv11, and HuscFv14, the non-cell-penetrable or cell-penetrable HuscFv4 effectively neutralized cellular entry of EBOV-like particles (VLPs). While all HuscFvs were found to bind cleaved GP (GPcl), their presumptive binding sites were markedly different, as determined by molecular docking. (4) Conclusions: The HuscFv4 could be a promising therapeutic agent against EBOV infection.